News

E-cigarettes don’t help cancer patients quit smoking


 

FROM CANCER

References

Though e-cigarette use increased among smokers diagnosed with cancer, it did not lead to greater success with tobacco cessation, according to a study among cancer patients referred to a tobacco quit program.

The prospective cohort study of 1,074 cancer patients found the prevalence of e-cigarette use increased from 10.6% of participants enrolled in 2012 to 38.5% of patients in 2013, with 92% of e-cigarette users reporting dual use with traditional cigarettes.

E-cigarette usage among cancer patients does not lead not to smoking cessation in most cases. Courtesy Wikimedia Commons/Martevax/Creative Commons License

E-cigarette usage among cancer patients does not lead not to smoking cessation in most cases.

At study entry, e-cigarette users were more nicotine dependent than were nonusers, had more prior quit attempts, and were more likely to be diagnosed with thoracic and head or neck cancers. Smoking cessation outcomes were collected from 414 patients, and after adjustment for nicotine dependence, number of past quit attempts, and cancer diagnosis, e-cigarette users were twice as likely to still be smoking at follow-up (odds ratio, 2.0; 95% confidence interval, 1.2-3.3; P less than .01), Sarah P. Borderud and her colleagues reported online Sept. 22 in Cancer [doi:10.1002/cncr.28811].

“Although we speculate that patients may be drawn to e-cigarette use for harm reduction, the findings of the current study provide no evidence to support oncologists recommending e-cigarette use among patients with cancer who are advised to quit smoking,” wrote Ms. Borderud, an epidemiologist at Memorial Sloan-Kettering Cancer Center, N.Y., and her colleagues.

No conflicts of interest were declared.

Recommended Reading

Keep an eye on the HPV p16 protein in head and neck cancer
MDedge Hematology and Oncology
Lobectomy suffices for surgery of small papillary thyroid cancers
MDedge Hematology and Oncology
Experimental lenvatinib extends PFS in iodine-refractory relapsed thyroid cancer
MDedge Hematology and Oncology
VIDEO: Lenvatinib ups PFS in thyroid cancer
MDedge Hematology and Oncology
Low-dose IMRT may be safe for patients with HPV-positive head and neck cancer
MDedge Hematology and Oncology
Insomnia with very short sleep duration is a risk factor for cancer
MDedge Hematology and Oncology
Lymph node mapping agent approval expanded to include head and neck cancer evaluation
MDedge Hematology and Oncology
Hypothyroid patients may need to surrender the car keys
MDedge Hematology and Oncology
A third of follicular thyroid lesions of undetermined significance were malignant
MDedge Hematology and Oncology
Hold the central lymph node dissection for small parathyroid tumors?
MDedge Hematology and Oncology